TITLE

Improved formulation of AIDS drug granted approval

PUB. DATE
December 1997
SOURCE
Drug Store News;12/8/97, Vol. 19 Issue 20, pCP4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the marketing approval granted to Hoffmann-LaRoche Inc. for the improved soft gelatin formulation of its protease inhibitor Invirase (saquinavir mesylate). Features of the product and its effectivity; Availability of Invirase.
ACCESSION #
16322

 

Related Articles

  • New & improved.  // Pharmaceutical Executive;Feb98, Vol. 18 Issue 2, p108 

    Reports that the US Food and Drug Administration has granted marketing clearance for Hoffman-La Roche's Fortovase (saquinavir), a soft gelatin formulation of the first available protease inhibitor. Indication of the drug.

  • saquinavir:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p195 

    An encyclopedia entry for saquinavir is presented. Saquinavir is the first protease inhibitor approved by the U.S. Food and Drug Administration. The drug was approved more quickly than any other new HIV drug at that time. Saquinavir is manufactured by Roche Laboratories, with the trade name...

  • Combination study of Invirase and Norvir starting.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187 

    Announces the clinical trial to be conducted by Hoffman-La Roche Inc. with Abbott Laboratories on the protease inhibitors Invirase in combination with Norvir and their effectiveness in the treatment of HIV/AIDS. Distinct mutation profile of Invirase.

  • Roche files saquinavir NDA.  // Drug Topics;9/18/95, Vol. 139 Issue 18, p8 

    Reports on Hoffman-LaRoche's submission of a new drug application for Invirase or saquinavir, a protease inhibitor used in the treatment of AIDS.

  • Pharmacy care Kit available from Roche.  // Drug Topics;10/10/94, Vol. 138 Issue 19, p8 

    Reports on the availability of a pharmacy counseling service from Roche Laboratories for patients on Roferon-A therapy.

  • Toradol labeling changed.  // Drug Topics;3/6/95, Vol. 139 Issue 5, p8 

    Reports on Roche Laboratories decision to change the labeling on its Toradol prescription pain reliever due to reports on side effects from improper use. Usage of the drug for pain management in postsurgical patients.

  • Program prevents pregnancies during tx.  // Dermatology Times;Sep95, Vol. 16 Issue 9, p3 

    Reports on the pregnancy prevention program conducted by Hoffman-La Roche Inc. during isotretinoin treatment for its patients.

  • La Roche lottery.  // Northern New Jersey Business;6/28/95, Vol. 3 Issue 13, p3 

    Reports on the US Food and Drug Administration's approval of the drug called Invirase, manufactured by Hoffman-La Roche.

  • Roche cuts controversial PCR fees, testing limits. Anderson, C. // Nature;1/30/1992, Vol. 355 Issue 6359, p379 

    Reports that Swiss-owned pharmaceutical company Hoffmann-La Roche, under pressure from researchers and diagnostic companies, agreed to lower its prices on its polymerase chain reaction (PCR) technology and lift restrictions on its use. The move should free the technology for widespread use in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics